Processing, please wait...

Dr Michael BENZAQUEN

Dermatologist
Switzerland

I completed medical education at the Faculty of Medicine of Marseille, Aix-Marseille University (Marseille, France), and ranked first among 3000 students in the first year of medical school. I then completed my residency in Dermatology at Assistance Publique Hôpitaux de Marseille, before a fellowship in the department of Dermatology at Hôpital Nord de Marseille. My professional experiences abroad in Columbia University (New York City, USA) and Inselspital - University Hospital of Bern (Bern, Switzerland) improved my clinical skills and knowledge in Dermatology, as well as my success in ECFMG certification (USA). I graduated from several inter-university diplomas in Internal Medicine, Pediatric Dermatology, Dermatological Laser and Dermatological Surgery. My works have been published in international peer-reviewed journals and I am regularly invited as speaker in international congresses. I investigated in various fields, ranging from infectious and inflammatory diseases to onco-dermatology, laser and surgery. As the Vice-President of the Scientific Council of the French Laser Group and the coordinator of the "NextGen Dermatology"  sessions of IMCAS congress, I encouraged young dermatologists in learning and practicing dermatological lasers. I am currently working in Switzerland as Head of the department of dermatological surgery at Inselspital-University Hospital of Bern and at Clinique La Prairie in Clarens-Montreux.

read more
add item add Michael BENZAQUEN

Michael BENZAQUEN's publications (39)

Mohs Micrographic Surgery for Cutaneous Squamous Cell Carcinoma.

Jun, 2024

The first-line treatment of the localized form of cutaneous squamous cell carcinoma (cSCC) remains surgical excision. Either conventional excision (CE) with margins or Mohs micrographic surgery (MMS) may be preferred, depending on the risk factors of cSCC, the characteristics of the tumor, and the available technical facilities. read more

Cancers

PET-CT vs brain MRI for the detection of cerebral metastases of melanoma, a 5-year retrospective study.

Apr, 2024

Melanoma patients present a high risk of developing extra cutaneous metastases. PET-CT is one of the preferred examinations for the staging of oncological patients. It is not the method of choice to detect brain metastases, but this technique has shown significant improvement and allows the detection of some of them, although it is unclear how it performs compared to the MRI, the current gold standard for diagnosing brain metastases. read more

Clinical and experimental dermatology

Nivolumab-induced eosinophilic fasciitis: An unusual immune-related adverse event that needs to be recognized by practitioners.

Oct, 2023

read more

Annales de dermatologie et de venereologie
Load more  

Michael BENZAQUEN's scientific societies (5)